S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT ID: NCT01412879

Last Updated: 2021-10-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2021-03-31

Brief Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients with mantle cell lymphoma undergoing peripheral blood stem cell transplantation.

PURPOSE: This randomized phase II trial studies how well giving rituximab together with combination chemotherapy or bendamustine hydrochloride followed by consolidation chemotherapy and peripheral blood stem cell transplantation works in treating older patients with previously untreated mantle cell lymphoma.

Detailed Description

OBJECTIVES:

• To estimate the 2-year progression-free survival (PFS) of patients with newly diagnosed mantle cell lymphoma (MCL) treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, dexamethasone (RHCVAD), methotrexate and cytarabine (MTX/Ara-C), and autologous stem cell transplant (ASCT) or rituximab and bendamustine (R-bendamustine) and autologous stem cell transplant and to select a regimen for further development.
• To assess the response rate and overall survival of patients with newly diagnosed MCL treated with R-HCVAD/MTX/Ara-C and ASCT or R-bendamustine and ASCT.
• To assess the toxicity and tolerability of R-HCVAD/MTX/Ara-C and ASCT or R-bendamustine and ASCT in patients with newly diagnosed MCL.
• To determine the prognostic value of quantitative minimal-residual disease (MRD) monitoring in the peripheral blood of MCL patients after induction therapy and serially after high-dose chemotherapy and ASCT on treatment outcome.
• To bank diagnostic tissue sections for future translational research studies.

OUTLINE: This is a multicenter study. Patients are stratified according to risk classification by Mantle Cell Lymphoma International prognostic Index (MIPI) score (low risk vs intermediate/high risk). Patients are randomized to 1 of 2 treatment arms.

• Arm I (induction therapy):

• Courses 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2.
• Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients undergo stem cell collection after completion of course 2.
• Each course is 21 days long and continues in the absence of disease progression or unacceptable toxicity.
• Arm II (induction therapy):

• Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment.
• Stem cell mobilization: Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.

Consolidation therapy: Patients receive one of the following preparative regimens.

• BCV* chemotherapy: Carmustine IV over 2 hours on days -6 to -4; etoposide IV over 4 hours on day -4; and cyclophosphamide IV over 1 hour on day -2.
• BEAM* chemotherapy: Carmustine IV over 4 hours on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2, and melphalan IV on day -1.
• TBI, etoposide, cyclophosphamide: Patients undergo total-body irradiation (TBI)** twice daily on days -8 to -5. Patients also receive etoposide IV on day -4 and cyclophosphamide IV over 1 hour on day -2.
• NOTE: * Patients 61 years of age or older receive either BCV or BEAM.
• NOTE: * *TBI may not be used for patients 61 years of age and older. Stem cell transplantation: Patients then undergo autologous peripheral blood stem cell transplantation on day 0.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually for up to 8 years from registration.

Conditions

Lymphoma

Keywords

contiguous stage II mantle cell lymphoma; noncontiguous stage II mantle cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm I

Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

cyclophosphamide

Intervention Type: DRUG

Given IV

cytarabine

Intervention Type: DRUG

Given IV

dexamethasone

Intervention Type: DRUG

Given PO or IV

doxorubicin hydrochloride

Intervention Type: DRUG

Given IV

leucovorin calcium

Intervention Type: DRUG

Given PO or IV

methotrexate

Intervention Type: DRUG

Given IV

vincristine sulfate

Intervention Type: DRUG

Given IV

Arm II

Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.

Group Type: EXPERIMENTAL

rituximab

Intervention Type: BIOLOGICAL

Given IV

bendamustine hydrochloride

Intervention Type: DRUG

Given IV

cyclophosphamide

Intervention Type: DRUG

Given IV

Interventions

rituximab

Given IV

Intervention Type: BIOLOGICAL

bendamustine hydrochloride

Given IV

Intervention Type: DRUG

cyclophosphamide

Given IV

Intervention Type: DRUG

cytarabine

Given IV

Intervention Type: DRUG

dexamethasone

Given PO or IV

Intervention Type: DRUG

doxorubicin hydrochloride

Given IV

Intervention Type: DRUG

leucovorin calcium

Given PO or IV

Intervention Type: DRUG

methotrexate

Given IV

Intervention Type: DRUG

vincristine sulfate

Given IV

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients must be planning to undergo stem cell transplantation within 84 days after day 1 of the last induction course
• Patients must have had at least 1.5 X 10^6 CD34^+ cells/kg collected and stored prior to second registration for stem cell transplantation

PATIENT CHARACTERISTICS:

• Zubrod performance status of 0-2
• Bilirubin ≤ 3 times upper limit of normal (ULN)
• Serum creatinine ≤ 2.0 times ULN
• Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Platelet count ≥ 100,000/mcL, unless due to bone marrow infiltration by lymphoma
• All patients ≥ 45 years of age must have an echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA )scan within 42 days prior to registration (whichever method is used at baseline must be used at restaging)

• Patients < 45 years of age should have ECHO/MUGA only if clinically indicated
• Patients with an ejection fraction < institutional lower limit of normal (ILLN) are not eligible
• Serum Lactate dehydrogenase (LDH) and a Complete Blood Count (CBC with differential must be measured within 28 days prior to registration
• Patients known to be HIV positive, or who have a history of solid organ transplantation, are ineligible
• No active hepatitis
• No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer; in situ cervical cancer; adequately treated Stage I or II cancer from which the patient is currently in complete remission; or any other cancer from which the patient has been disease-free for 5 years
• Pregnant or nursing women may not participate
• Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

SWOG Cancer Research Network

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steven H. Bernstein, MD

Role: PRINCIPAL_INVESTIGATOR

James P. Wilmot Cancer Center

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, United States

Aurora Presbyterian Hospital

Aurora, Colorado, United States

Boulder Community Hospital

Boulder, Colorado, United States

Penrose Cancer Center at Penrose Hospital

Colorado Springs, Colorado, United States

St. Anthony Central Hospital

Denver, Colorado, United States

Porter Adventist Hospital

Denver, Colorado, United States

Presbyterian - St. Luke's Medical Center

Denver, Colorado, United States

St. Joseph Hospital

Denver, Colorado, United States

Rose Medical Center

Denver, Colorado, United States

CCOP - Colorado Cancer Research Program

Denver, Colorado, United States

Swedish Medical Center

Englewood, Colorado, United States

North Colorado Medical Center

Greeley, Colorado, United States

Littleton Adventist Hospital

Littleton, Colorado, United States

Sky Ridge Medical Center

Lone Tree, Colorado, United States

Hope Cancer Care Center at Longmont United Hospital

Longmont, Colorado, United States

McKee Medical Center

Loveland, Colorado, United States

Parker Adventist Hospital

Parker, Colorado, United States

St. Mary - Corwin Regional Medical Center

Pueblo, Colorado, United States

Exempla Lutheran Medical Center

Wheat Ridge, Colorado, United States

Tunnell Cancer Center at Beebe Medical Center

Lewes, Delaware, United States

CCOP - Christiana Care Health Services

Newark, Delaware, United States

Florida Hospital Cancer Institute at Florida Hospital Orlando

Orlando, Florida, United States

St. Joseph Regional Medical Center

Lewiston, Idaho, United States

Illinois CancerCare - Bloomington

Bloomington, Illinois, United States

Graham Hospital

Canton, Illinois, United States

Illinois CancerCare - Canton

Canton, Illinois, United States

Illinois CancerCare - Carthage

Carthage, Illinois, United States

Memorial Hospital

Carthage, Illinois, United States

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Chicago, Illinois, United States

Hematology and Oncology Associates

Chicago, Illinois, United States

Decatur Memorial Hospital Cancer Care Institute

Decatur, Illinois, United States

Eureka Community Hospital

Eureka, Illinois, United States

Illinois CancerCare - Eureka

Eureka, Illinois, United States

Galesburg Clinic, PC

Galesburg, Illinois, United States

Illinois CancerCare - Galesburg

Galesburg, Illinois, United States

Illinois CancerCare - Havana

Havana, Illinois, United States

Mason District Hospital

Havana, Illinois, United States

Kellogg Cancer Care Center

Highland Park, Illinois, United States

Provena St. Mary's Regional Cancer Center - Kankakee

Kankakee, Illinois, United States

Illinois CancerCare - Kewanee Clinic

Kewanee, Illinois, United States

North Shore Oncology and Hematology Associates, Limited - Libertyville

Libertyville, Illinois, United States

Illinois CancerCare - Macomb

Macomb, Illinois, United States

McDonough District Hospital

Macomb, Illinois, United States

Cardinal Bernardin Cancer Center at Loyola University Medical Center

Maywood, Illinois, United States

Illinois CancerCare - Monmouth

Monmouth, Illinois, United States

Cancer Care and Hematology Specialists of Chicagoland - Niles

Niles, Illinois, United States

BroMenn Regional Medical Center

Normal, Illinois, United States

Community Cancer Center

Normal, Illinois, United States

Illinois CancerCare - Community Cancer Center

Normal, Illinois, United States

Community Hospital of Ottawa

Ottawa, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Ottawa

Ottawa, Illinois, United States

Cancer Treatment Center at Pekin Hospital

Pekin, Illinois, United States

Illinois CancerCare - Pekin

Pekin, Illinois, United States

Proctor Hospital

Peoria, Illinois, United States

CCOP - Illinois Oncology Research Association

Peoria, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Peoria

Peoria, Illinois, United States

Methodist Medical Center of Illinois

Peoria, Illinois, United States

Illinois CancerCare - Peru

Peru, Illinois, United States

Illinois Valley Community Hospital

Peru, Illinois, United States

Illinois CancerCare - Princeton

Princeton, Illinois, United States

Perry Memorial Hospital

Princeton, Illinois, United States

Hematology Oncology Associates - Skokie

Skokie, Illinois, United States

Illinois CancerCare - Spring Valley

Spring Valley, Illinois, United States

Regional Cancer Center at Memorial Medical Center

Springfield, Illinois, United States

St. Francis Hospital and Health Centers - Beech Grove Campus

Beech Grove, Indiana, United States

Reid Hospital & Health Care Services

Richmond, Indiana, United States

McFarland Clinic, PC

Ames, Iowa, United States

Siouxland Hematology-Oncology Associates, LLP

Sioux City, Iowa, United States

Mercy Medical Center - Sioux City

Sioux City, Iowa, United States

St. Luke's Regional Medical Center

Sioux City, Iowa, United States

Cancer Center of Kansas, PA - Chanute

Chanute, Kansas, United States

Cancer Center of Kansas, PA - Dodge City

Dodge City, Kansas, United States

Cancer Center of Kansas, PA - El Dorado

El Dorado, Kansas, United States

Cancer Center of Kansas - Fort Scott

Fort Scott, Kansas, United States

Cancer Center of Kansas-Independence

Independence, Kansas, United States

Cancer Center of Kansas, PA - Kingman

Kingman, Kansas, United States

Lawrence Memorial Hospital

Lawrence, Kansas, United States

Cancer Center of Kansas, PA - Liberal

Liberal, Kansas, United States

Cancer Center of Kansas, PA - McPherson

McPherson, Kansas, United States

Cancer Center of Kansas, PA - Newton

Newton, Kansas, United States

Cancer Center of Kansas, PA - Parsons

Parsons, Kansas, United States

Cancer Center of Kansas, PA - Pratt

Pratt, Kansas, United States

Cancer Center of Kansas, PA - Salina

Salina, Kansas, United States

Cancer Center of Kansas, PA - Wellington

Wellington, Kansas, United States

Associates in Womens Health, PA - North Review

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Medical Arts Tower

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Wichita

Wichita, Kansas, United States

CCOP - Wichita

Wichita, Kansas, United States

Via Christi Cancer Center at Via Christi Regional Medical Center

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Winfield

Winfield, Kansas, United States

Lucille P. Markey Cancer Center at University of Kentucky

Lexington, Kentucky, United States

Union Hospital of Cecil County

Elkton, Maryland, United States

Hickman Cancer Center at Bixby Medical Center

Adrian, Michigan, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Mercy Memorial Hospital - Monroe

Monroe, Michigan, United States

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Mercy and Unity Cancer Center at Mercy Hospital

Coon Rapids, Minnesota, United States

Fairview Southdale Hospital

Edina, Minnesota, United States

Mercy and Unity Cancer Center at Unity Hospital

Fridley, Minnesota, United States

Hutchinson Area Health Care

Hutchinson, Minnesota, United States

HealthEast Cancer Care at St. John's Hospital

Maplewood, Minnesota, United States

Minnesota Oncology - Maplewood

Maplewood, Minnesota, United States

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Minneapolis, Minnesota, United States

Hennepin County Medical Center - Minneapolis

Minneapolis, Minnesota, United States

New Ulm Medical Center

New Ulm, Minnesota, United States

Humphrey Cancer Center at North Memorial Outpatient Center

Robbinsdale, Minnesota, United States

CCOP - Metro-Minnesota

Saint Louis Park, Minnesota, United States

Park Nicollet Cancer Center

Saint Louis Park, Minnesota, United States

Regions Hospital Cancer Care Center

Saint Paul, Minnesota, United States

United Hospital

Saint Paul, Minnesota, United States

St. Francis Cancer Center at St. Francis Medical Center

Shakopee, Minnesota, United States

Lakeview Hospital

Stillwater, Minnesota, United States

Ridgeview Medical Center

Waconia, Minnesota, United States

Willmar Cancer Center at Rice Memorial Hospital

Willmar, Minnesota, United States

Minnesota Oncology - Woodbury

Woodbury, Minnesota, United States

Saint Louis University Cancer Center

St Louis, Missouri, United States

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

St Louis, Missouri, United States

Cancer Institute of New Jersey at Hamilton

Hamilton, New Jersey, United States

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Cancer Institute of New Jersey at Cooper - Voorhees

Voorhees Township, New Jersey, United States

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, United States

SUNY Upstate Medical University Hospital

Syracuse, New York, United States

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Grandview Hospital

Dayton, Ohio, United States

Good Samaritan Hospital

Dayton, Ohio, United States

David L. Rike Cancer Center at Miami Valley Hospital

Dayton, Ohio, United States

Samaritan North Cancer Care Center

Dayton, Ohio, United States

CCOP - Dayton

Dayton, Ohio, United States

Community Cancer Center

Elyria, Ohio, United States

Hematology Oncology Center

Elyria, Ohio, United States

Blanchard Valley Medical Associates

Findlay, Ohio, United States

Middletown Regional Hospital

Franklin, Ohio, United States

Wayne Hospital

Greenville, Ohio, United States

Charles F. Kettering Memorial Hospital

Kettering, Ohio, United States

Lima Memorial Hospital

Lima, Ohio, United States

Northwest Ohio Oncology Center

Maumee, Ohio, United States

St. Charles Mercy Hospital

Oregon, Ohio, United States

North Coast Cancer Care, Incorporated

Sandusky, Ohio, United States

Flower Hospital Cancer Center

Sylvania, Ohio, United States

Mercy Hospital of Tiffin

Tiffin, Ohio, United States

Toledo Hospital

Toledo, Ohio, United States

St. Vincent Mercy Medical Center

Toledo, Ohio, United States

Medical University of Ohio Cancer Center

Toledo, Ohio, United States

CCOP - Toledo Community Hospital

Toledo, Ohio, United States

St. Anne Mercy Hospital

Toledo, Ohio, United States

Toledo Clinic, Incorporated - Main Clinic

Toledo, Ohio, United States

UVMC Cancer Care Center at Upper Valley Medical Center

Troy, Ohio, United States

Fulton County Health Center

Wauseon, Ohio, United States

Ruth G. McMillan Cancer Center at Greene Memorial Hospital

Xenia, Ohio, United States

Clackamas Radiation Oncology Center

Clackamas, Oregon, United States

Providence Milwaukie Hospital

Milwaukie, Oregon, United States

Providence Newberg Medical Center

Newberg, Oregon, United States

Willamette Falls Hospital

Oregon City, Oregon, United States

Providence Cancer Center at Providence Portland Medical Center

Portland, Oregon, United States

CCOP - Columbia River Oncology Program

Portland, Oregon, United States

Providence St. Vincent Medical Center

Portland, Oregon, United States

Geisinger Cancer Institute at Geisinger Health

Danville, Pennsylvania, United States

Geisinger Hazleton Cancer Center

Hazleton, Pennsylvania, United States

Geisinger Medical Group - Scenery Park

State College, Pennsylvania, United States

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

Wilkes-Barre, Pennsylvania, United States

Cancer Centers of the Carolinas - Faris Road

Greenville, South Carolina, United States

Cancer Centers of the Carolinas - Grove Commons

Greenville, South Carolina, United States

Greenville Hospital Cancer Center

Greenville, South Carolina, United States

CCOP - Greenville

Greenville, South Carolina, United States

Cancer Centers of the Carolinas - Greer Medical Oncology

Greer, South Carolina, United States

Cancer Centers of the Carolinas - Seneca

Seneca, South Carolina, United States

Cancer Centers of the Carolinas - Spartanburg

Spartanburg, South Carolina, United States

Baylor University Medical Center - Dallas

Dallas, Texas, United States

Fredericksburg Oncology, Incorporated

Fredericksburg, Virginia, United States

Island Hospital Cancer Care Center at Island Hospital

Anacortes, Washington, United States

Overlake Cancer Center at Overlake Hospital Medical Center

Bellevue, Washington, United States

St. Joseph Cancer Center

Bellingham, Washington, United States

Olympic Hematology and Oncology

Bremerton, Washington, United States

Highline Medical Center Cancer Center

Burien, Washington, United States

Providence Centralia Hospital

Centralia, Washington, United States

Providence Regional Cancer Partnership

Everett, Washington, United States

St. Francis Hospital

Federal Way, Washington, United States

Swedish Medical Center - Issaquah Campus

Issaquah, Washington, United States

Columbia Basin Hematology

Kennewick, Washington, United States

Skagit Valley Hospital Cancer Care Center

Mount Vernon, Washington, United States

Providence St. Peter Hospital Regional Cancer Center

Olympia, Washington, United States

Harrison Poulsbo Hematology and Onocology

Poulsbo, Washington, United States

Good Samaritan Cancer Center

Puyallup, Washington, United States

Harborview Medical Center

Seattle, Washington, United States

Minor and James Medical, PLLC

Seattle, Washington, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Group Health Central Hospital

Seattle, Washington, United States

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

Seattle, Washington, United States

Polyclinic First Hill

Seattle, Washington, United States

University Cancer Center at University of Washington Medical Center

Seattle, Washington, United States

North Puget Oncology at United General Hospital

Sedro-Woolley, Washington, United States

Cancer Care Northwest - Spokane South

Spokane, Washington, United States

Evergreen Hematology and Oncology, PS

Spokane, Washington, United States

Franciscan Cancer Center at St. Joseph Medical Center

Tacoma, Washington, United States

Allenmore Hospital

Tacoma, Washington, United States

CCOP - Northwest

Tacoma, Washington, United States

MultiCare Regional Cancer Center at Tacoma General Hospital

Tacoma, Washington, United States

St. Clare Hospital

Tacoma, Washington, United States

Southwest Washington Medical Center Cancer Center

Vancouver, Washington, United States

Northwest Cancer Specialists at Vancouver Cancer Center

Vancouver, Washington, United States

Wenatchee Valley Medical Center

Wenatchee, Washington, United States

Mary Babb Randolph Cancer Center at West Virginia University Hospitals

Morgantown, West Virginia, United States

Gundersen Lutheran Center for Cancer and Blood

La Crosse, Wisconsin, United States

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States

Countries

United States

Other Identifiers

S1106

Identifier Type: OTHER

Identifier Source: secondary_id

U10CA032102

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CDR0000707601

Identifier Type: -

Identifier Source: org_study_id